Alternative Antibiotics to Augmentin

Primary Alternatives Based on Clinical Context

The American Academy of Otolaryngology-Head and Neck Surgery recommends cefdinir, cefpodoxime proxetil, or cefuroxime axetil as first-line alternatives to Augmentin for most respiratory tract infections, with respiratory fluoroquinolones reserved for patients with recent antibiotic exposure or significant comorbidities 1, 2, 3
Cefdinir is the most preferred alternative due to excellent patient acceptance, good activity against S. pneumoniae, and activity against H. influenzae similar to cefuroxime axetil 1, 2
Cefpodoxime proxetil is often regarded as the preferred treatment when high-dose amoxicillin or amoxicillin-clavulanate fails or is intolerable, with activity similar to cefuroxime axetil and cefdinir against S. pneumoniae but greater activity against H. influenzae 1
The Infectious Diseases Society of America recommends levofloxacin (750 mg daily) or moxifloxacin for patients with comorbidities, recent antimicrobial use, or risk factors for drug-resistant S. pneumoniae 3

For mild disease without recent antibiotics, the American Academy of Otolaryngology-Head and Neck Surgery recommends using cefpodoxime proxetil, cefuroxime axetil, or cefdinir as first choice, with cefdinir preferred for children due to palatability 2
For patients with penicillin allergy, cefdinir, cefpodoxime proxetil, or cefuroxime axetil are appropriate due to negligible cross-reactivity with penicillins, with cefdinir preferred based on high patient acceptance 2
The Infectious Diseases Society of America recommends considering respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin) for adults with comorbidities 3

High-dose amoxicillin (90 mg/kg/day in children; 1g three times daily in adults) targets ≥93% of S. pneumoniae, with respiratory fluoroquinolones providing excellent DRSP coverage 3
Cefpodoxime proxetil has the greatest activity against H. influenzae among oral cephalosporins, with cefdinir and cefuroxime axetil providing adequate coverage 1

Failure to respond after 72 hours should prompt either a switch to alternate antimicrobial therapy or reevaluation of the patient, with consideration of CT scan, fiberoptic endoscopy, or sinus aspiration and culture if symptoms persist despite appropriate antibiotic therapy 2, 6

For acute bacterial sinusitis in adults, cefpodoxime proxetil, cefuroxime axetil, or cefdinir are recommended for mild-moderate disease, with respiratory fluoroquinolone for patients with recent antibiotic exposure or comorbidities 2, 3
For community-acquired pneumonia (outpatient), the Infectious Diseases Society of America recommends doxycycline or a macrolide for patients without comorbidities, and respiratory fluoroquinolone or combination of high-dose amoxicillin (or ceftriaxone if parenteral feasible) plus a macrolide for patients with comorbidities or recent antibiotic use 3